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Summary 
Ott-4 is a transcription factor expressed in the pluripo- 
tent progenitor cells of the early mouse embryo. Addi- 
tional factors are required for the distal activation of 
genes in differentiated cells containing ectopically ex- 
pressed Ott-4. Here we show that Ott-4 and El A are 
sufficient for distance-independent activation of the 
basal transcription machinery. The ratio of Ott-4 to 
ElA is critical for transcriptional activation, because 
higher levels of either factor are less efficient. Activa- 
tion depends on a transactivation domain linked to the 
POU domain of Ott-4 and also on the conserved do- 
main 3 of the 289R El A protein. This domain is required 
for binding to the C-terminal part of Ott-4 including the 
POU domain. Our results indicate that EIA can serve 
as a bridging factor between Ott-4 and the basal initia- 
tion complex, and we postulate that an El A-like factor 
acts as a cellular bridging factor of Ott-4 in pluripotent 
cells. 
Introduction 
Protein-protein interactions are of fundamental impor- 
tance for transcriptional regulation (reviewed in Lewin, 
1990; Ptashne and Gann, 1990). To determine the rele- 
vance of protein-protein interactions for regulatory pro- 
cesses during development, we studied the interaction of 
two well-known proteins, ElA and Ott-4. 
Infection of early mouse embryos with SV40 and poly- 
omavirus demonstrates that early multipotent cell lineages 
do not support viral replication (reviewed in Kelly and Con- 
damine, 1982). Until the eight-cell or early morula stage, 
all cells of the embryo are totipotent, contributing to all 
cell lineages in any embryonic or extraembryonic tissue. 
During blastocyst formation cells differentiate into two 
types, those of the inner cell mass (ICM) and those of the 
extraembryonictrophectoderm, thefirstfullydifferentiated 
cell type. When blastocysts are infected with SV40 or poly- 
omavirus, expression of viral genes is detected in trophec- 
todermal cells but not in the ICM. If later embryonic stages 
are infected, viral genes are also not detected in pluripo- 
tent cell populations, e.g., the early embryonic ectoderm 
until day 9 of gestation. In contrast, differentiated cells 
are permissive for viral infection (reviewed in Kelly and 
Condamine, 1982). 
A detailed functional analysis of postinfective viral gene 
expression in early mouse embryos is made difficult by the 
limited amount of material. Therefore, embryonal carci- 
noma (EC) cells have been used as a model system to 
study viral gene expression in pluripotent stem cells. EC 
cells resemble early mouse embryonic cells in many re- 
spects. They can be maintained in an undifferentiated 
state, can be induced to differentiate into cells resembling 
the derivatives of all three germ layers, and can participate 
in normal embryonic development (Mintz and Illmensee, 
1975; Evans and Kaufman, 1981; Martin, 1981). The lack 
of expression of SV40 and polyomavirus in early pluripo- 
tent cells correlates with the lack of their expression in 
undifferentiated EC cells (reviewed in Kelly and Con- 
damine, 1982). This block is due to repression of their 
enhancers (Borrelli et al., 1984; Gorman et al., 1985; Vel- 
cich and Ziff, 1985). Repression can be overcome by cer- 
tain mutations in the viral enhancer, allowing expression 
of the viral genome in undifferentiated EC cells, as de- 
scribedforthepolyomavirusenhancer(reviewed in Sleigh, 
1985). When the EC cells are induced to differentiate, the 
block to viral gene expression is relieved. One of these 
polyoma enhancers that is active in EC cells contains a 
point mutation and is not repressed by ElA (Hen et al., 
1986), whereas wild-type polyoma enhancer is (Borrelli et 
al., 1984). An activity similar to that of ElA seems to be 
responsible for enhancer repression in undifferentiated 
EC cells. 
An ElA-like activity has originally been postulated to 
explain the growth of certain adenovirus mutants in EC 
stem cells (Imperiale et al., 1984). Deletion of the El A gene 
prevents the growth of adenoviruses on differentiated cells 
by blocking the subsequent expression of other adenovi- 
rus genes (Berk et al., 1979; Jones and Shenk, 1979). 
However, since such viruses grow in EC stem cells, ElA 
apparently can be replaced by a factor present in these 
cells, thus named ElA-like factor or ElA-like activity (lm- 
periale et al., 1984; La Thangue and Rigby, 1987). Two 
categories of cellular genes are affected by ElA (Svens- 
son and Akusjarvi, 1984; for reviews see Berk, 1986; Flint 
and Shenk, 1989). The genes of the 70 kd heat shock 
protein (Kao and Nevins, 1983) and P-tubulin (Stein and 
Ziff, 1984) are activated by El A, whereas the genes of the 
class I antigens of the major histocompatibility complex 
(MHC) are repressed (Schrier et al., 1983). ElA could not 
be shown to bind to DNA in a sequence-specific manner 
(Ferguson et al., 1985; Chatterjee et al., 1988) but requires 
viral or cellular proteins to exert its function. The interac- 
tion with DNA might be mediated by such proteins (Ko et 
al., 1986). In agreement with this notion, ElA has been 
shown to interact with multiple cellular proteins (Yee and 
Branton, 1985; Harlow et al., 1986). 
The well-characterized octamer motif mediates tran- 
scriptional activity and is found in various cellular promot- 
ers and enhancers, e.g., the immunoglobulin heavy chain 
(IgH) enhancer (reviewed in Schreiber et al., 1989a). The 
IgH enhancer is active in lymphoid cells, whereas it is 
inactive in fibroblasts. However, in the presence of ectopic 
El A, the IgH enhancer is repressed in lymphoid cells (Hen 
et al., 1985) and is activated in fibroblast cells (Borrelli 
et al., 1986). Because the octamer sequence of the IgH 
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enhancer is the major determinant of its cell type-specific 
expression (reviewed in Kemler and Schaffner, 1990) pro- 
teins interacting with this motif may also interact with ElA 
and thereby mediate both transcriptional activation and 
repression, The octamer motif confers transcriptional ac- 
tivity also in undifferentiated F9 ceils (Scholer et al., 1989b) 
where Ott-4 (also termed Ott-3 or NF-A3) and Ott-6 are 
expressed but not Ott-2 (Lenardo et al., 1989; Scholer et 
al., 1989a). Thus, in F9 cells the octamer is active in the 
presence of the El A-like activity, and in lymphoid cells the 
IgH enhancer is repressed by ElA. 
In the blastocyst a number of octamer-binding proteins 
are present and the activity mediated by the octamer is 
restricted to the ICM (Scholer et al., 1989b). Thus, the 
activity pattern of the octamer motif in the blastocyst is 
reciprocal to the expression pattern of SV40 and poly 
omavirus. Furthermore, the Ott-4 gene is expressed in 
pluripotent cells and not in differentiated cells. During the 
time when the block of viral replication in the embryo is 
relieved (day 9 of gestation), Ott-4 expression is restricted 
to the primordial germ cells (Rosner et al., 1990; Schdler 
et al., 1990b). Therefore, the expression of Ott-4 and the 
viral gene expression is reciprocal both in the embryo and 
in the EC cells. A possible link between both patterns is 
the EIA-like factor, which might not only repress certain 
viral enhancers but also stimulate Ott-4-mediated gene 
expression. 
In this report we show that transactivation by Ott-4 is 
strongly stimulated in the presence of ElA in differenti- 
ated cells and that this stimulation can even occur from a 
downstream enhancer. Stimulation depends on a trans- 
activation domain linked to Ott-4 (Okamoto et al., 1990), 
indicating that the activation domain of EiA (Lillie and 
Green, 1989) or another coactivator (Liu and Green, 1990) 
cannot substitute for that of Ott-4. In contrast to strong 
stimulation of Ott-Cmediated gene activation, Ott-2 and 
Ott-1 only slightly stimulate transcription in the presence 
of El A. Stimulation by these proteins also depends on 
their functional transactivation domains. We suggest that 
distance-independent transcriptional activation reflects 
thefunctionof ElAasabridgingfactorallowingOctfactors 
to interact with TATA box factor(s). This notion is sup- 
ported by cotransfection experiments of ElA and Ott-4 
expression vectors into HeLa cells, where a certain ratio 
of both is necessary for optimal transcriptional activation. 
Increasing ElA or Ott-4 destroys activation, probably via 
squelching (Ptashne, 1988) or surface saturation of partici- 
pating factor(s). Binding of ElA to Ott-4 was demonstrated 
with proteins translated in vitro. We postulate that ElA can 
substitute for a bridging factor in pluripotent progenitor 
cells and that this is the ElA-like factor. 
Results 
In F9 Cells the Octamer Enhancer 6W Is Repressed 
by the ElA Product(s) 
In F9 stem cells and B cells a single octamer motif is active 
irrespective of its distance from the TATA box. Tandemly 
arranged octamer motifs function as strong enhancers ac- 
tive in both F9 and B cells (Gerster et al., 1987; Schtjler 
et al., 1989b). However, such enhancers are not sufficient 
to activate transcription in HeLa cells, even when Ott-2, 
Ott-4, and Ott-6 are ectopically expressed (Miiller-lmmer- 
gliick et al., 1988; Schiiler et al., 1990b, Suzuki et al., 
1990). These observations suggest that additional activat- 
ing proteins are absent or repressing proteins are present 
in HeLacells, when compared with F9 or Bcells. Transcrip- 
tion is stimulated considerably when the octamer motif 
and the TATA box are in close proximity, demonstrating 
that the Ott factors are not intrinsically inactivated in HeLa 
cells (Miiller-lmmergliick et al., 1988; Rosner et al., 1990; 
Schdler et al., 1990b; Suzuki et al., 1990). 
The effect of ectopically expressed adenovirus 5 (Ad5) 
El A on the octamer motif was examined in F9 cells (Figure 
1). The target vector used contains six tandem repeats of 
an IgH fragment in front of a tk minimal promoter, the 
IgH fragment harboring an octamer motif and a uE4 site 
(p6WtkCAT; Figure 1 D). A constant amount of this target 
vector was cotransfected with varying amounts of an ElA 
expression vector (Figure 1E). Increasing amounts of the 
ElA expression vector reduced CAT activity (Figure 1A) 
to a level of a vector containing an inactive octamer mutant 
(p6FdtkCAT). Since the low but measurable level of 
p6FdtkCAT was not affected by ElA (data not shown), we 
conclude that the octamer motif mediates repression by 
ElA. 
To determine if ElA affects the binding activity of any 
Ott protein, aliquots of the transfected F9 cells were exam- 
ined in the electrophoretic mobility shift assay (EMSA). 
In contrast to the dramatic decrease in CAT activity, no 
change is detectable for any of the complexes when ElA 
is expressed (Figure 1B). Therefore, binding of the Ott 
proteins is not affected. 
One possible cause for the decrease in transcriptional 
activity could be that Ott factors are competed by binding 
sites in the expression vector. However, this is unlikely, 
because a 5fold molar excess of the 6W enhancer cloned 
in Bluescript did not reduce transcriptional activation (data 
not shown). Therefore, the Ott factors are not limiting in 
the transactivation experiment outlined above. 
The ElA transcription unit encodes several related pro- 
teins through the production of alternatively spliced mRNAs 
(reviewed in Berk, 1986). The 13s mRNA encodes a pro- 
tein of 289 amino acids (289R); and the 12s mRNA en- 
codes a protein of 243 amino acids (243R). The larger 
protein contains a domain of 46 conserved amino acids 
that is required for transactivation (reviewed in Braithwaite 
et al., 1991). To examine if repression is due to any of 
these proteins, expression vectors containing either 12s 
or 13s ElA cDNA were cotransfected with the reporter 
plasmid into F9 cells (Figures 1C and 1E; Weigel et al., 
1990). The expression vector without cDNA sequences 
was added to the same total amount (Figure 1 E; Gunning 
et al., 1987). Large amounts of the 13s expression vector 
reduced CAT activity to an extent comparable to the whole 
ElA transcription unit, whereas the same amount of 125 
expression vector only slightly reduced the CAT activity. 
Therefore, the repression of enhancer-mediated activa- 
tion is mainly due to the 289R ElA protein. 
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The Octamer Is Not Directly Affected by ElA 
Protein(s) in F9 Cells 
Repression of the 6W enhancer activity in F9 ceils resem- 
bles repression of the IgH enhancer by ElA in B cells (Hen 
et al., 1985). However, the mechanism of repression might 
be different in both cases. Several publications have out- 
lined an effect of the ElA transcription unit on the differen- 
tiation state of F9 cells (Montano and Lane, 1987; Velcich 
and Ziff, 1989; Nelson et al., 1990; Weigel et al., 1990). 
Both the binding activity of Ott-4 and Ott-6 and transcrip- 
tional activation by the octamer motif are reduced upon 
differentiation of F9 stem cells (Scholer et al., 1989b). 
Therefore, differentiation caused by ElA might be a rea- 
son for the reduced octamer activity described above. 
To test if ElA affects proteins interacting with the oc- 
tamer motif, a reporter gene containing an octamer next 
to the 8-globin TATA box (Schiiler et al., 1990b) was co- 
transfected with increasing amounts of the pElA vector 
into F9 cells. The CAT activity remained constant, and 
thus the activity of the Ott factors is not influenced by 
ElA when the octamer is close to the TATA box (data not 
shown). 
In 293 Cells the 6W Enhancer Is Strongly Activated 
by Low Amounts of Ott-4 
An inverse cotransfection experiment was designed with 
cells containing EIA (Figure 2). For this purpose, pGWtk- 
CAT was transfected with different amounts of a strong 
Ott-4 expression vector (pCMV-OcM; Schdler et al., 
1990b) into 293 cells. High amounts of pCMV-Oct4 re- 
pressed (2-to 3.fold) expression of CAT as compared with 
a vector with Ott-4 in the antisense orientation (Figure 2A, 
lanes 1 and 7) or with Bluescript DNA (data not shown). 
However, with lower amounts of pCMV-Oct4 strong stimu- 
lation was achieved with an optimum at 0.25 trg of DNA 
(lane 5); with even lower amounts transcriptional activation 
decreased again (lane 6). When aliquots of the cells were 
Figure 1. Repression of the 6W Enhancer in 
F9 Stem Cells by EIA 
Varying amounts (indicated at the top) of an 
El A expression vector were cotransfected with 
the reporter plasmid p6WtkCAT into F9 cells. 
Aliquots of the transfected F9 cells were used 
for (A) the CAT assay (30%) and(B) the EMSA. 
The extracts were incubated for 1 hr in the CAT 
assay; to demonstrate the gradual decrease of 
the CAT activity, a 3 hr exposure of the experi- 
ment is shown. In the binding reaction 0.5 tug 
of poly(dl-dC) was incubated with the octamer 
probe 1W. In (C), cotransfection was as in (A) 
except that pH6APr-1-neo-12s and pH6APr-l- 
neo-13S were used as expression vectors and 
pHBAPr-1-neo as carrier DNA. Ten percent of 
the cell extract was incubated for 1 hr. In (D) 
the reporter plasmid and in (E) the expression 
vectors are schematically outlined. 
examined in the EMSA, decreasing amounts of trans- 
fected pCMV-Oct4 resulted in decreasing amounts of 
Ott-4 (Figure 26). The highest CAT signal was obtained 
with an intermediate amount of Ott-4 (Figures 2A and 2B, 
lane 5). When the same experiment was performed in cells 
without ElA, transcription was not stimulated with any 
amount of Ott-4 (Scholer et al., 1990b; see below). This 
indicates that not only expression of both Ott-4 and ElA 
is needed for transcriptional activation, but in addition a 
certain ratio of Ott-4 and ElA (or a factor induced by El A) 
appears to be required. Because a low amount of Ott-4 is 
sufficient for transcriptional activation, modification as a 
major cause of repression can be ruled out by this ex- 
periment. 
In p6WtkCAT the distance between the 6W enhancer 
and the TATA box is about 150 bp (Schbler et al., 1990b). 
To test if Ott-4 can stimulate transcription from a more 
distant position, 6W was cloned downstream of the CAT 
gene (Figure 2D). When this plasmid was cotransfected 
with pCMV-Oct4 in 293 cells, transcription was activated 
up to 15-fold as compared with Ott-4 expressed in the 
antisense orientation (Figure 2C). Although the stimulation 
is lower than from the 5’position (7.5fold), this result dem- 
onstrates that Ott-4 can also activate transcription from a 
downstream position in the presence of ElA. 
A Certain Ratio of Ott-4 and ElA Is Necessary for 
Enhancer Stimulation in HeLa Cells 
Expression of ElA in F9 cells and of Ott-4 in 293 cells 
indicates that a certain ratio of both factors is needed for 
optimal transcriptional activation. To test this in detail, vari- 
ous ratios of Ott-4 and ElA were cotransfected with a 
constant amount of p6WtkCAT into HeLa cells (Figure 3). 
In this experiment four different amounts of the El A vector 
were combined with five different amounts of pCMV-OcM, 
resulting in 20 different combinations. Aliquots of the 
transfected HeLa cells were used for the CAT assay (Fig- 
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ure 3, left) and for the EMSA to determine the amount of 
expressed Ott-4 (right). 
When high amounts of the ElA vector were used (10 ug 
in subset A) any amount of pCMVOct4 increased tran- 
scription above the level that was obtained in the absence 
of Ott-4, with an optimum at 0.8 ug of pCMVOct4 DNA. 
Thesameoptimum wasobtained with25 pgof ElAvector 
(subset B), but the activity had decreased. With even less 
ElA vector DNA (0.8 ug in subset C) the overall activity 
had not only decreased again, but also the optimum had 
changed, now at 0.2 ug of pCMV-Oct4 DNA. With the 
lowest amount of ElA vector DNA (0.2 ug in subset D) 
no transcriptional activation could be achieved with any 
amount of pCMV-OcM. Both the optimum and the overall 
activity changed in a way indicating that Ott-4 and ElA 
have to be present in a certain ratio and concentration 
to mediate transcriptional activation. The EIA vector to 
pCMV-Oct4 ratio has to be higher than 3 to obtain optimal 
transcriptional activation at a given ElA concentration, 
therefore no activation is found in Figure 30. 
In some cases expression of the CAT gene is higher 
without than with Ott-4 (Figure 3D). This basal signal is 
probably due to El A, because ElA can stimulate pGWtk- 
CAT in HeLa cells (Figure 3G). Therefore, expresston of 
Ott-4 inhibits a p6WtkCAT activity caused by El A. ElA 
stimulates the expression of p6WtkCAT about 4-fold more 
than that of p6FdtkCAT (Figure 3G), suggesting that ElA 
also activates Ott-1. A decrease in expression due to 
Ott-4 is also seen with 293 cells (Figure 2; compare lanes 
1 and 7). 
Figure 2. Activation of Ott-4 by EIA in 293 
Cells 
Line 293 cells were cotransfected with different 
amounts of the Ott-4 expression vector (indi- 
cated at the top) and with p6WtkCAT as a re- 
porter. Aliquots of the transfected 293 cells 
were used for (A) the CAT assay (30%) and (B) 
the EMSA. The extracts were incubated for 1 
hr in the CAT assay. In the EMSA 0.5 ug of 
poly(dl-dC) was coincubated with the IW 
probe. In (C) two different reporter plasmids 
(with the 6W enhancer either 5’or 3’of the CAT 
gene) were cotransfected with 0.25 ng of Ott-4 
expression vector and carrier DNA. Thirty per- 
cent of the extract was incubated for 2 hr. In (D) 
the reporter plasmids and in (E) the expression 
vector used are schematically outlined. The 
open ellipse represents the POU-specific do- 
main and the shaded ellipse the POU homeo- 
domain. 
Enhancer Stimulation Depends on Expression 
of the 13s El A Gene Product 
In F9 cells the 289R protein dramatically repressed 
GW-mediated activation of transcription, whereas this was 
only reduced slightly by the 243R protein (Figure 1C). To 
determine which of the two is responsible for activation, 
increasing amounts of the same expression vectors were 
cotransfected with a constant amount of the Ott-4 expres- 
sion vector and the reporter plasmid (Figure 4). With two 
different 13s expression vectors the 6W enhancer could 
be activated, whereas with the 12s expression vector only 
a slight stimulation could be determined (activation by 
pHPAPr-neo-13s not shown). In parallel an ElA mutant in 
the 13Sspecific domain was tested that has been shown 
to be less efficient in transactivation experiments (Lillie et 
al., 1986; Lillie and Green, 1989; Liu and Green, 1990). 
This mutant is about 3-to 4-fold less efficient in the trans- 
activation assay than the unmutated ElA 289R protein. 
Enhancer Activation Is Higher by Ott-4 
Than by Ott-2 
To test if Ott-2 could replace Ott-4, varying amounts of 
Ott-2 and Ott-4 were expressed in 293 cells and com- 
pared (Figure 5). The results of the CAT assay demon- 
strate that transcriptional activation by Ott-2 occurs but is 
lower than activation by Ott-4 (Figure 5A, upper left). The 
relative amounts of expressed Ott proteins were exam- 
ined by analyzing aliquots of the transfected cells in the 
EMSA (Figure 58). 
Two other expression vectors were tested in the trans- 
2;vatior-r and Repression of Ott-4 by ElA 
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Figure 3. Activation of Ott-4 by ElA Depends on a Certain Ratio of 
Both Factors 
HeLa cells were cotransfected with different amounts of the Ott-4 and 
ElA expression vectors (as indicated at the bottom of [A] to [D]) and 
with p6WtkCAT as a reporter plasmid. Aliquots of the transfected cells 
were used for the CAT assay (30%; 90 min) and the EMSA (6 ug 
of whole-cell extract). The CAT assay is shown at the left and the 
corresponding EMSA at the right of each panel. The free probe is not 
HeLa 
Figure 4. Ott-4 Activates the 6W Enhancer in the Presence of the 
289R EIA Protein 
In (A) HeLa cells were cotransfected with different amounts of ElA 
expression vectors (as indicated at the top), 0.2 ug of pCMV-Oct4, and 
p6WtkCAT as a reporter plasmid. Aliquots of the transfected cells were 
used for the CAT assay (30%; 90 min). In (6) the reporter plasmid and 
in (C) the expression vectors are schematically outlined. 
activation experiment in 293 cells (Figure 5A, upper left). 
The first vector harbored Ott-4 in the antisense orienta- 
tion, the other a cDNA that was derived from a naturally 
occurring Ott-2 mRNA (A. Stoykova et al., submitted). 
pCMV-MiniOctP contained almost only the Ott-2 POU do- 
main (Figure 5D). In both cases transcriptional activation 
by the 6W enhancer could not be achieved. Therefore, the 
Ott-2 POU domain is not sufficient for stimulation of the 
6W enhancer. Several other controls were included in this 
experiment. First, the effect of each vector on the en- 
hancer with the octamer mutant was tested in 293 and 
HeLa cells. None of them influenced the residual tkCAT 
expression, indicating that transcriptional activation is 
specific for the octamer (Figure 5A, right). 
To study transactivation by Ott-2 and Ott-4 in HeLa 
cells, an intermediate DNA amount (5 to 10 ug) had been 
used for transfection of the expression vectors (Mtiller- 
lmmergliick et al., 1988; Rosner et al., 1990; Schbler et 
al., 1990b). With these DNA amounts activation is low or 
absent in 293 cells (Figure 2A). Therefore, varying 
amounts of the same expression vectors were also trans- 
fected into HeLa cells together with p6WtkCAT (Figure 5A, 
shown because the length of electrophoresis had been prolonged. In 
(E) the reporter plasmid and in (F) the expression vectors used are 
schematically outlined. Open ellipses represent the POU-specific do- 
main and shaded ellipses the POU homeodomain. The numbering of 
the Ott-4 sequences is according to Schdler et al. (199Oa). In (G) is 
shown the evaluation of an experiment in which the effect of ElA on 
either wild-type (p6WtkCAT) or a mutated octamer motif (p6FdtkCAT) 
had been tested (for the mutated octamer see Figure 5C). 
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B Different expression vectors were cotrans- 
fected with reporter plasmids into 293 and 
HeLa cells. The expression vectors express 
Ott-2, the POU domain of Ott-2,Oct-4, or Ott-4 
Mini-OctP 
antisense sequences. The reporter plasmids 
contain either a wild-type (p6WtkCAT) or a mu- 
tated octamer motif (p6FdtkCAT). Aliquots of 
the transfected cells were used for (A) the CAT 
assay (30%; 30 min) and (B) the EMSA (6 pg 
of whole-cell extract). In (A) an evaluation of the 
CAT assay is shown; in (8) binding of the Ott-2 
and Mini-Oct2 is shown in the presence of 0.5 
jrg of poly(dl-dC). The different amounts of the 
expression vectors used for transfection are 
indicated in the figure. In (C)the reporter plas- 
mids and in (D) the expression vectors are 
schematically outlined. Open ellipses repre- 
sent the POU-specific domain and shaded el- 
lipses the POU homeodomain. 
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lower left). However, at best a slight increase could be al., 1989b), demonstrating that nuclear transport is not 
evaluated with the Ott-2 and Ott-4 expression vectors, affected (Figure 66). Therefore, the transactivating do- 
and thus activation of the 6W enhancer depends on ElA main of Ott-4 and the conserved region 3 in ElA are re- 
gene product(s). quired for enhancer stimulation. 
Enhancer Stimulation by Ott-4 Can Be Achieved by 
Different Transactivation Regions 
Both Ott-4 and ElA contain transactivating domains; in 
the case of Ott-4 the domain is “acidic” (Okamoto et al., 
1990; Lillie and Green; 1989; Martin et al., 1990). The ElA 
activating region appears to interact with a cellular target 
not required for the activation by transcription factors with 
acidic activating regions (Martin et al., 1990). Therefore, 
we examined if ElA is sufficient for transcriptional activa- 
tion if Ott-4 lacks the acidic domain. Two 5’ deletion mu- 
tants of Ott-4 were expressed in 293 cells and tested for 
activation of p6WtkCAT (Figure 6). The deletions either 
included the whole N-terminal region up to the POU do- 
main or about half of it (Figure 6D). Binding of both proteins 
was unaffected, but transcriptional activation was im- 
paired (Figures 6A and 6B). To ascertain that the deletion 
mutants are transported to the nucleus, nuclear extracts 
were prepared and analyzed in the EMSA (Schreiber et 
Stimulation of 6W is higher by Ott-4 than by Ott-2 (Fig- 
ure 5). In contrast to the whole Ott-2 protein, its POU 
domain could not activate the 6W enhancer. Therefore, as 
outlined for Ott-4, stimulation by Ott-2 depends on its 
transactivation domain(s). Two regions in Ott-2 contribute 
to transactivation; the stronger one is rich in glutamine 
residues (Gerster et al., 1990; Mijller-lmmergltick et al., 
1990; Tanaka and Herr, 1990). Such a glutamine-rich re- 
gion is absent in Ott-4. To distinguish the contribution of 
the POU domain from that of the transactivation do- 
main(s), the glutamine-rich region of Ott-2 was cloned in 
the N-terminal region of both Ott-4 deletion mutants (Fig- 
ure 6D). With this region transactivation could be restored 
to levels between that of Ott-2 and Ott-4 (Figure 6A). Be- 
cause the activity of the Ott-2-Ott-4 hybrid is above that 
of Ott-2, we conclude that both POU domains can interact 
with ElA (or a factor induced by it) and that this interaction 
is stronger for the Ott-4 POU domain. For a given POU 
domain, the strength of enhancer stimulation then de- 
pends on the transactivation domain linked to it. 
Activation and Repression of Ott-4 by EIA 
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Figure 6. Ott-4 Needs a Transactivation Do- 
main for Enhancer Activation by ElA 
Different Ott-2 and Ott-4 expression vectors 
were cotransfected with p6WtkCAT into 293 
cells. The Ott-4 expression vectors contain ei- 
ther Ott-4 or truncated forms of Ott-4. The 
amounts of the expression vectors are indi- 
cated at the bottom of (A); the 0 value has been 
determined by transfection of Ott-4 in the anti- 
sense orientation. Aliquots of the transfected 
293 cells were used in parallel for (A) the CAT 
assayand(B)the EMSA(3ugof nuclearextract 
incubated with the IW probe and 0.5 pg Of 
poly(dl-dC). In the CAT assay 30% of the cells 
transfected were incubated for 30 min. In (A) 
an evaluation of the CAT assay is given. In (6) 
only the complexes of Ott-4 and its mutants 
are presented. Therefore, the free probe and 
the complexes common in each lane are not 
shown (e.g., the Ott-1 complex). In (C) the re- 
porter plasmid and in (D) the expression vectors used are schematically outlined. Open ellipses represent the POU-specific domain and shaded 
ellipses the POU homeodomain. The numbering of the Ott-4 sequences is according to Schdler et al. (1990a). 
Ott-4/B-Related Protein-Protein Complexes Are 
Formed in 293 Cells 
To achieve transcriptional activation from a distance, 
Ott-4 is thought to interact with other factor(s), such as 
EIA or a factor induced by ElA. To test this notion, 293 
extracts with Ott-4 were examined for protein-protein 
complexes. Two bands correlate with the presence and 
the intensities of Ott-4 and Ott-5 in 293 cells, thus named 
tentatively Ott-4/5-related complexes (Figure 7A; com- 
pare lanes 1 and 2 with lanes 3 and 4). 
Ott-4 cannot stimulate transcription without the trans- 
activation domain even when ElA is present (Figure 6). To 
determine if the truncated Ott-4 proteins still form Ott-4- 
related complexes, aliquots of the extracts with these pro- 
teins were examined in the EMSA (data not shown; for a 
different purpose the 20ct-4 deletion mutant and its re- 
lated complex are shown in Figures 8A and 8B). Again 
complexes with lower mobility are formed with a pattern 
similar to that of Ott-4 and its truncated forms, indicating 
that factor binding to Ott-4 is not affected when the N-ter- 
minal region of Ott-4 is missing. 
The Ott-415related complexes are labile because they 
are destroyed by competitor DNA, bromophenol blue, or 
xylene xyanol (Figure 7A; compare lanes 3 and 4 with lane 
5). When low amounts of Ott-4 were expressed in 293 
cells, no Ott-4/5-related complexes could be detected in 
the EMSA (data not shown). Due to their lability, any at- 
tempt to immunoprecipitate the Ott-4/5-related com- 
plexes according to Harlow et al. (1986) were not suc- 
cessful. 
Figure 7. EIA Binds to Ott-4 In Vitro 
(A) The 293 extracts of Figure 2 were analyzed 
in the EMSA with or without 0.1 pg of poly(dl- 
dC) as indicated at the top. Either Bluescript 
DNA (lanes 1,2, and 6) or different amounts Of 
CMV-Oct4 DNA were transfected (lane 3,0.25 
ug; lanes 4 and 5, 1 pg of DNA). 
(B) Ott-4 and ElA RNAs were translated in dif- 
ferent combinations in a reticulocyte lysate as 
indicated at the top, and analyzed with the 1 W 
probe in the EMSA. Either sense (s) or anti- 
sense (a) ElA RNAwas used for translation. fn 
thepresenceof El Aprotein twocomplexesare 
formed in addition to 06-4 and Ott-5 (cOm- 
plexes 1 and 2). No poly(dl-dC) was used in the 
binding reaction. 
(C) In vitro translation of 12s and 13s El A ANA 
in the presence of [%B]methionine. The transla- 
tion products were separated with a 15% poly- 
acrylamide gel (Laemmli, 1970). 
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Figure 8. The 289R ElA Protein Forms a 
Complex with Ott-4 
(A) HeLa whole-cell extracts containing a dele- 
tion mutant of Ott-4 (named 20ct-4) and differ- 
ent ElA proteins were analyzed in the EMSA. 
The different expression vectors as indicated 
at the top are 13s (pH3G-13s) 13s 1098 
(pH3G-13S/i098), 12s (pH8APr-1-neo-12s). 
Lane 4, The 289R protein has been expressed 
without 20ct-4. ElA/2Oct-4 indicates the posi- 
tion of the protein-protein complex. This com- 
plex migrates between two nonspecific com- 
plexes, which are most probably due to the 
same protein. Subtle differences in the binding 
conditions or extract concentrations alter the 
distribution of both drastically (data not shown). 
(B) HeLa whole-cell extracts containing 20ct-4 
and either wild-typeor mutated (1098) EIA pro- 
teins were analyzed in the EMSA. Wild-type 
EIA has been used for lanes 1,3, and 5; the 
mutated EIA protein for lanes 2 and 4. In the 
experiment either 1 ng of poly(dl-dC) (lane 1) 
or 3 ng of Fab fragment of monoclonal antibody 
M73 was added (lanes 4 and 5) (Harlow et al., 
1985). The extracts were preincubated without 
(lane 1) or with 6 mM spermidine (lanes 2 to 4) 
(see Experimental Procedures). Due to a prolonged electrophoresis the unbound probe is not shown. Fab/ElAI20ct-4 indicates the position of the 
protein-protein complex shifted by the Fab fragment. 
(C) Purification of the M73 Fab fragments. After isolation of M73 monoclonal antibodies with protein A-Sepharose chromatography (lane 2) the 
antibodies were digested with papain (lane 3). The Fc fragments were separated from the Fab fragments by protein A-Sepharose chromatography 
(lane 4). An aliquot of each purification step was applied to a 12.5% polyacrylamide gel (Laemmli, 1970). Purification is according to Harlow and 
Lane (1988). 
(D) Prolonged electrophoresis of a HeLa whole-cell extract showing that the complex detected without competitor DNA (lane 1) has a different 
mobility than Ott-I (lane 2). Only Ott-1 and the nonspecific complex are shown. 
In Vitro Translated Ott-4 and ElA 
Bind to Each Other 
The functional analysis indicates that the 289R protein 
encoded by the 13s mFlNA is the most likely partner in the 
Ott-4/5-related complexes. To test if 289R and Ott-4 can 
bind to each other, Ott-4 RNA and sense or antisense 
RNA of 13s El A were translated in vitro in different combi- 
nations (Figure 78). When Ott-4 and El A sense RNAwere 
translated in vitro, two additional complexes with lower 
mobility were obtained (lane 2), whereas Ott-4 RNA trans- 
lated alone or together with 13s ElA antisense RNA gave 
only Ott-4 and Ott-5 complexes (lanes 1 and 3). No ElA- 
containing complex is detectable with 13s ElA sense or 
antisense RNA translated alone (lanes 4 and 5) or with 12s 
ElA RNA (data not shown). Therefore, the complexes are 
specific for the 289R protein. The presence of the two 
El A-Ott-4 complexes reduces the Ott-4 signal to about 
50% of that obtained without ElA (compare lane 2 with 
lanes 1 and 3). 
The two ElA-Ott4 complexes might be due to two 
translation products, although 13s and 12s ElA trans- 
lated in the presence of [%]methionine in each case only 
gave one prominent product (Figure 7C). Both El A-Ott-4 
complexes might also be due to binding of one and two 
ElA proteins to one Ott-4 or vice versa. Similar to the 
complexes found with 293 cell extracts, these complexes 
are labile because they are destroyed by either low 
amounts of competitor DNA, bromophenol blue, or xylene 
xyanol. 
The Conserved Domain 3 of the 289R ElA Protein 
Is Required for Binding to Ott-4 
In the presence of Ott-4, 13s ElA expression vectors 
strongly activate the 6W enhancer (Figure 4). In contrast, a 
vector expressing the smaller splicing product only slightly 
activated this enhancer. To correlate the functional assay 
with the binding assay, a deletion mutant of Ott-4 was 
coexpressed with different ElA proteins in HeLacells. The 
extracts of these cells were subsequently used to deter- 
mine the efficiency of El A-Ott-4 complex formation (Fig- 
ure 8A). The Ott-4 deletion mutant was useful because it 
facilitated the separation of the ElA-Ott-4 complex from 
the strong nonspecific complex with lower mobility. This 
strong band is not due to Ott-1 binding, because both 
complexes are separated after a prolonged gel electropho- 
resis (Figure 8D). With the HeLa extract containing the 
289R protein, a strong 20ct-4-related complex was ob- 
tained (lane 1). The 13s 1098 mutation also gave a protein 
that formed a complex with Ott-4, although this complex 
was less prominent (lane 2). When an extract containing 
the 243R protein was examined, a very faint band with a 
slightly higher mobility could be detected after a prolonged 
exposure (lane 3; longer exposure not shown). 
Coexpression of 135 ElA and Ott-4 RNA in a reticulo- 
cyte lysate shows that both proteins can bind to each other 
(Figure 7B). The presence of ElA in the Ott-4-related 
complex derived from HeLa cells was determined by anti- 
bodies against ElA (Harlow et al., 1985). Monoclonal anti- 
bodies were incubated with extracts containing the 20ct- 
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4-related complex. However, although this complex was 
abolished by different antibodies, an additional shift in the 
EMSA could not be obtained. This was most probably due 
to precipitation of the complex (data not shown). To avoid 
precipitation, the Fab fragments of several antibodies 
were purified (Figure 8C). These were then added to ex- 
tracts containing the 20ct-4 protein and either the 289R 
EIA protein or its mutated counterpart (Figure 88). With 
poly(dl-dC) only the Ott-4 deletion mutant is detected 
(20ct-4; Figure 88, lane 1). Without competitor DNA and 
with spermidine a 20ct-4-related complex was found with 
both ElA proteins (Figure 88, lanes 2 and 3). After binding 
of the M73 Fab fragments these complexes were retarded 
in the EMSA (Figure 8B, lanes 4 and 5). Therefore, we 
conclude that Ott-4 and ElA can bind to each other. 
Discussion 
A comparison of the expression of Ott-4 (Rosner et al., 
1990; Schdler et al., 1990b) and the permissivityfor growth 
of certain viruses during early mouse embryogenesis and 
in EC cells (reviewed in Kelly and Condamine, 1982) re- 
veals a striking complementary pattern. Unlike Ott-4, 
genes of SV40 and polyomavirus are not expressed in 
pluripotent cells, whereas expression is reversed in differ- 
entiated cells. The fact that enhancers of both viruses are 
considered to be repressed by an ElA-like factor (Imperi- 
ale et al., 1984; Gorman et al., 1985; Hen et al., 1986) 
prompted us to investigate if the same factor might stimu- 
late transcriptional activation by Ott-4. 
As the initial step to elucidate such a relationship, we 
studied the influence of adenovirus ElA on the activity of 
Ott-4.Asshown in this report, El AandOct-4canstimulate 
transcription synergistically from adistance. Both proteins 
have to be present in a certain ratio; higher expression of 
either results in a loss of transcriptional activation. Since 
ElA and Ott-4 can bind to each other in vitro, ElA is an 
intriguing candidate for a bridging factor of Ott-4 in vivo. 
Enhancer stimulation by Ott-4 can be achieved either by 
its own transactivation domain or by one of Ott-2. There- 
fore, the previously described transactivation domain of 
ElA is not sufficient. Instead, this domain appears to be 
important for ElA to interact with Ott-4. ElA also stimu- 
lates O&P-mediated gene activation, which is signifi- 
cantly lower than that of Ott-4. Similar to Ott-4, Ott-2 
depends on a functional transactivation domain. 
A Possible Mechanism of ElA-Mediated Activation 
In HeLa cells a weak promoter consisting only of an oc- 
tamer next to the TATA box (pDPCAT) was readily induced 
by Ott-4 and Ott-2, whereas in p6WtkCAT the more dis- 
tally located 6W enhancer could not be activated (SchBler 
et al., 1990b). Our results indicate that Ott-4 and Ott-2 are 
sufficient to activate via a proximal octamer motif but need 
additional factor(s) for distance-independent activation. 
The simplest model is that Ott-4 needs a bridging factor 
to be connected with the basal initiation complex and that 
ElA is the most likely candidate (Figure 9, middle). Such 
a bridging factor present in pluripotent but not in differenti- 
ated cells can explain why expression of Ott-4 in HeLa 
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Figure 9. A Model for Activation and Repression of Ott-4 by ElA 
A bridging factor(BRF), either a cellular component or El A, recognizes 
with one surface Ott-4 and with another the basal initiation complex, 
thus activating transcription from a distance (middle). Activation is lost 
when the amounts of Ott-4 (top) or of EIA (bottom) are increased or 
if the transactivation domain of Ott-4 is deleted. Activation is restored 
when the Ott-2 glutamine-rich region is fused to otherwise inactive 
Ott-4 deletion mutants. According to the model, high amountsof Ott-4 
result in squelching of the BRF, while high amounts of ElA result 
in a mode of repression we term surface saturation. Due to surface 
saturation the BRF interaction sites of Ott-4 and the basal initiation 
complex contain bound BRFs, thus preventing both sites from being 
brought together. In pluripotent cells a stem cell-specific BRF is postu- 
lated. Since ElA can substitute for this factor, one candidate for the 
BRF in pluripotent cells is the ElA-like factor. 
cells is not sufficient to activate via a distant octamer. 
Supposing thatthesimilarityof ElAand the El A-like factor 
can be extended to their role as bridging factors, the El A- 
like factor might be a bridging factor specific for embryonic 
stem cells. 
To study the activity of the octamer in early embryogene- 
sis, fertilized oocytes had been microinjected with pGWtk- 
LacZ containing the same promoter as pGWtkCAT, culti- 
vated to the blastocyst stage and subsequently analyzed 
for LacZ expression (Schaler et al., 1989b). Although the 
Ott-4 gene is expressed throughout the blastocyst 
(Rosner et al., 1990; Schiiler et al., 1990b), only cells of 
the ICM were positive for LacZ expression, indicating that 
this promoter is not active in trophectodermal cells 
(Schbler et al., 1989b). One possible reason for this is that 
the El A-like activity needed for 6W stimulation is missing 
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in these cells. In agreement with this notion, expression of 
SV40 and polyomavirus is readily detectable in the troph- 
ectoderm and not in the ICM (reviewed in Kelly and Con- 
damine, 1982) and the El A-like factor appears to be 
down-regulated during the differentiation of EC stem cells 
(La Thangue and Rigby, 1987, and references therein). 
The dependence of activation on the Ott-4/ElA ratio 
probably reflects two different effects: ElA as a bridging 
factor would have to bind to two different proteins, whereas 
Ott-4 had to interact with only one protein. When Ott-4 
is overexpressed, Ott-4-bridging factor complexes would 
be prevented from binding DNA by an excess of Ott-4 
bound to the octamer motif (Figure 9, top). In this case 
repression is acombination of squelching and competition 
(Levine and Manley, 1989; Ptashne and Gann, 1990). 
An excess of ElA might saturate the interaction sites of 
Ott-4 and the basal initiation complex bound to the pro- 
moter, thus preventing transcriptional activation (Figure 9, 
bottom). 
Repression by surface saturation postulates an interac- 
tion of ElA with TATA box factors, which is independent 
of other promoter elements. In agreement with this notion, 
the tk promoter is stimulated by ElA (Figure 3G and data 
not shown). A stimulation of TATA-binding factor(s) by ElA 
has been analyzed in detail for other transcription units, 
such as adenovirus El 6, j3-globin, hsp70, histone Hl, and 
c-fos, where the TATA element is essential for transactiva- 
tion by ElA (Nevins, 1981; Green et al., 1983; Wu et al., 
1987; Simon et al., 1988). These genes have the TATAA 
sequence in common and are stimulated lo- to 30-fold. In 
contrast, the early SV40 promoter contains a TATA ele- 
ment that is not induced by ElA (TATTTAT; Simon et al., 
1988). It is possible that distinct TATA factors interact with 
thedifferent TATAsequencesandonlytheTATAA-binding 
factor is stimulated by ElA. 
The tk TATA element is stimulated 3-to 4-fold. Although 
this TATA is similar to the @globin element (CATATAA), 
it contains an additional T (CATATTAA) and thus does 
not exactly fit with the consensus sequence TATAA. Two 
different factors with distinct binding specificities or a sin- 
gle TATA factor recognizing both TATA elements in a dif- 
ferent manner might explain why the tk TATA is less acti- 
vated than the 6-globin TATA. 
Surface saturation can also explain why the activity of 
the octamer is repressed in F9 cells by ElA, although 
binding of none of the Ott factors is affected. If F9 cells 
contain a certain amount of bridging factor optimal for 
transactivation, any additional bridging factor would satu- 
rate the binding sites of the participating proteins with the 
same consequences as outlined above (Figure 9, bottom). 
Although the F9 cell experiments indicate a bridging factor 
required for distance-independent activation, they cannot 
exclude the possibility that the bridging activity of the 
bridging factor is affected by El A, e.g., by modification, or 
that its expression is down-regulated by El A. 
Although Ott-4 and ElA clearly bind to each other in 
vitro, this does not exclude the possibility that ElA induces 
a cellular factor that itself serves as a bridging factor in 
vivo. However, we think that this is unlikely, because tran- 
scriptional activation depends on a defined ratio of Ott-4 
and ElA and not on the total amount of El A. For the same 
reasons we think that posttranslational modifications are 
not the major cause of transcriptional activation by Ott-4. 
The lability of the El A-Oct4complex to competitor DNA 
was somewhat surprising but could be due to at least two 
reasons. The most plausible one is that ElA is directly 
competed by DNA, because the 289R ElA protein nonspe- 
cifically binds to DNA, including poly(dl-dC) (Chatterjee et 
al., 1988). Alternatively, a cellular factor might be neces- 
sary to stabilize the El A-Ott-4 complex. If this factor binds 
nonspecifically to DNA it could be competed out, thus 
weakening the El A-Ott-4 complex. This kind of stabiliza- 
tion has been proposed for the interaction of VP18 with 
Ott-1 . A cellular factor, distinct from Ott-1 , binds to VP1 6 
in the absence of target DNA and is necessary for VP16- 
mediated complex assembly with Ott-1 (Kristie and Sharp, 
1990; Xiao and Capone, 1990). 
A slightly different model has been proposed for ElA- 
mediated activation of ATF-2 (Liu and Green, 1990). In that 
case, ElA is attached on one surface to the DNA-binding 
protein ATF-2 and on another to an additional component 
necessary for transcriptional activation. This third factor 
is supposed to support ATF-2 with an (acidic) activating 
region. In contrast to ATF-2, Ott-4 has a transactivation 
domain (Okamoto et al., 1990), and therefore ElA alone 
is sufficient for transcriptional activation. Transcriptional 
activation is lost when the transactivation domain of Ott-4 
is deleted, indicating that this domain cannot be substi- 
tuted by a third component or by ElA (Martin et al., 1990). 
Thus the mechanism of transcriptional activation by ElA 
appears to be different for ATF-2 and Ott-4. 
The 243R El A protein at best binds weakly to Ott-4. This 
protein lacks the conserved domain 3, which is present in 
the larger 289R ElA protein. A mutation in this domain 
that has been reported to affect promoter binding strongly 
(Lillie and Green, 1989) also reduces binding of ElA to 
Ott-4 approximately 2- to 3-fold. This mutant protein is 
also less active in enhancer stimulation than wild-type 
ElA. The ElA mutation 1098 changes amino acid 180 
from a glycine to an aspartic acid. Lillie and Green showed 
that an ElA segment containing the conserved domain 3 
(121 to 223) fused to the DNA-binding domain of the yeast 
transcriptional activator GAL4 could activate transcription 
of the E4 promoter even in the absence of GAL4 binding 
sites. However, transactivation was abolished with the mu- 
tant ElA protein. In contrast, when GAL4 sites were intro- 
duced 240 bp upstream of the El B TATA, both the wild- 
type and the mutant El A proteins activated transcription to 
a similar extent. Therefore, the mutation can be overcome 
when linked to a DNA-binding domain. It is possible that 
ElA binds via the conserved domain 3 to Ott-4 and that 
binding is slightly affected by the 1098 mutation. If this 
kind of interaction occurs, another surface of ElA might 
be responsible for linking the El A-Ott4 complex to the 
basal initiation complex. 
The conserved domain 3 of ElA has two interesting 
features: it is acidic and it binds zinc (Gulp et al., 1988). 
POU domains contain four basic clusters, one in each 
center of the POU-specific subdomains and one at both 
ends of the POU homeodomain (SchBler, 1991). These 
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basic clusters are regions to which the 289R protein ElA 
might bind. Alternatively, the possible zinc finger might 
interact with Ott-4. A mutational analysis of Ott-4 will de- 
fine which region is responsible for the El A-Ott4 inter- 
action. 
Repression in Lymphoid Cells and Activation in 
Fibroblast Cells: ElA and the Other Ott Factors 
ElA activates stimulation of transcription by Ott-2 and 
even Ott-1, although the effect of both these proteins is 
much lower than that of Ott-4. Again, stimulation depends 
on transactivation domain(s), indicating that the mecha- 
nism of transcriptional activation is similar for these Ott 
factors. The difference with respect to activation by each 
Ott factor is most probably due to the interacting surfaces. 
An example for different interacting surfaces has been 
reported for Ott-1 and Ott-2. The herpes simplex protein 
VP16 specifically activates Ott-I (Gerster and’ Roeder, 
1988) because it binds to the homeodomain of Ott-1 and 
not to that of Ott-2 (Stern et al., 1989). In addition, the 
transactivation domain of Ott-4 might be stronger than for 
both other Ott factors. This is possible, because transcrip- 
tional activation via an octamer next to a TATA box is 
stronger for Ott-4 than for Ott-2 (SchBler et al., 1990b; 
Suzuki et al., 1990). 
In certain cases expression of Ott-4 can slightly de- 
crease transcriptional activation to levels below that when 
only Ott-1 is present, probably due to squelching of ElA 
by Ott-4 (Figures 3 and 5). As outlined above, ElA might 
not serve as a bridging factor for Ott-1 when it is titrated 
out by Ott-4 (Figure 9, top). This kind of repression has to 
be kept in mind when the effect of Ott-4 (or of any other 
Ott factor) on a possible target gene is tested. As a conse- 
quence the Ott factor tested can behave as a repressor, 
although under physiological conditions it activates a 
gene. A titration experiment might help to investigate the 
activating and repressing potential of a certain transcrip- 
tion factor (see Figure 2). Ott-4 might also exert both activi- 
ties in vivo. This is not unlikely, because depending on its 
context the octamer motif confers both repression and 
activation in F9 cells (Lenardo et al., 1989; Schijler et al., 
1990b). Actually, most of the eukaryotic transcriptional re- 
pressors also function as activators (Levine and Manley, 
1989). 
Activation of the octamer motif by ElA has also been 
shown by Chellappan and Nevins (1990). They suggested 
that this is due to increased Ott-1 binding; however, their 
results cannot exclude the possibility that Ott-1 activates 
transcription also by additional protein-protein interac- 
tions. In their experiments CV-1 cells had been infected 
with Ad5 for 18 hr and therefore most of the cells might 
have contained ElA. In our experiments no changes in 
Ott-1 binding were detectable. This might be due to a 
limited number of transfected cells too low to give a signal 
above that of Ott-1 from untransfected cells. 
An interaction of ElA with Ott-2 and Ott-1 would also 
explain why the IgH enhancer is repressed by ElA in 
lymphoid cells but is stimulated in fibroblasts (Hen et al., 
1985; Borrelli et al., 1986). Surface saturation could ac- 
count for repression of the IgH enhancer by ElA in 
lymphoid cells (Hen et al., 1985). If an Ott-2 bridging factor 
in lymphoid cells were replaceable by ElA, too high 
amounts of ElA would lead to saturation of the binding 
sites on Ott-2 and on the basal initiation complex (Figure 
9, bottom). In fibroblasts ElA might serve as a bridging 
factor, resulting in activation of Ott-I (Figure 3G; Chellap- 
pan and Nevins, 1990) and, as a consequence, in activa- 
tion of the IgH enhancer (Borrelli et al., 1986). 
The ElA-like Factor as a Potential Bridging 
Factor in EC Cells 
ElA can confer on primary cells the capacity for unlimited 
proliferation (Houweling et al., 1980; Ruley, 1983). ElA 
may be substituting for the cellular function of a growth 
regulator and so immortalize a cell. The genes conferring 
cell immortality are not known; therefore, it is of interest to 
consider gene regulation in stem cells that acquire a finite 
lifespan when they differentiate. It is characteristic of a 
number of stem cell types that expression of certain 
differentiation-specific functions commences with the loss 
of potential for unlimited growth. An example of this re- 
lationship between growth and expression of differen- 
tiation-specific functions is provided by EC cells. MHC 
class I antigens, which are repressed by ElA of Ad12 
immortalized primary cells (Schrier et al., 1983), are ex- 
pressed only at a very low level in undifferentiated EC cells 
(Croce et al., 1981; Morello et al., 1982). Thus, for the MHC 
class I antigens, ElA may reproduce a state in immortal- 
ized primary cells normally found in undifferentiated cells. 
Although it is not known whether the repression of MHC 
class I antigen genes in EC cells or in Ad12 immortalized 
cells involves enhancer elements present in the MHC 
class I antigen genes, a clear example of the dependence 
of enhancer function on the differentiation state is pre- 
sented by polyomavirus. The enhancer element for the 
polyoma early promoter is inactive in undifferentiated EC 
cells but becomes transcriptionally active after the cells 
are induced to differentiate (reviewed in Kelly and Con- 
damine, 1982). Furthermore, rearrangements of the en- 
hancer elements enable mutant polyomaviruses to grow 
in undifferentiated EC cells (reviewed in Sleigh, 1985). 
One of these mutants contains a point mutation in the 
enhancer. This enhancer is not repressed by El A products 
(Hen et al., 1986), whereas wild-type polyoma enhancer is 
(Borrelli et al., 1984). 
Taken together, our results suggest that EIA substitutes 
for the El A-like activity as a bridging factor between Ott-4 
(or other transcription factors) and the basal initiation com- 
plex. Similar to the ElA product(s), the ElA-like activity 
might interact with other factors, resulting in activation 
or repression of certain genes in pluripotent cells. As a 
consequence, changes in the amount of only the El A-like 
activity could up- or down-regulate several genes simulta- 
neously upon differentiation of the pluripotent progenitor 
cells. Because Ott-4 is the candidate for a factor inter- 
acting with the ElA-like activity, we now might have a tool 
to screen for the El A-like activity. These studies may help 
in understanding gene regulation during early embryogen- 
esis and also may give an idea as to why pluripotent cells 
have the capacity for unlimited proliferation. 
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Experimental Procedures 
Cell Lines and Transfection; Assay for Chloramphenicol 
Acetyltransferase 
HeLa, 293, and F9 stem cells were grown and transfected as described 
elsewhere (Schdler and Gruss, 1984; Schdler et al., 1989b). Briefly, 
approximately 10” cells were plated onto 10 cm tissue culture dishes 
3 hr before addition of the calcium phosphate precipitate and refed 30 
min before addition of the precipitate. The precipitate was left on the 
cells for 20 hr; thereafter the cells were refed and harvested after an 
additional 8 hr. Twenty percent of the harvested cells were used for 
the microextraction procedure, and the rest for the CAT assay, which 
was performed as outlined before (Schbler and Gruss, 1984; Schdler 
et al., 1990b). The standard exposure time was 16 hr. The total amount 
of DNA in the transactivation experiment was 26 pg, of which 6 ng was 
from reporter plasmid. Except when outlined otherwise in the figure 
legends, Bluescript DNA (Stratagene) was used as carrier to achieve 
the total amount necessary for optimal transfection. 
Recombinant Plasmids and Oligonucleotides 
The reporter plasmids (p6WtkCAT and p6FdtkCAT) and the expres- 
sion vector pCMV-Oct4 have been described previously (Schdler et al., 
1969b, 1 SSOb). p6WtkCAT was created by cloning the 6W enhancer in 
the Smal site of pBLCAT2 (Luckow and Schutz, 1967). 
Oct.2 and Oct.4 Expression Vectors 
pCMV-OctP has been described by Mtiller-lmmergliick et al. (1988) 
pCMV-MiniOctP by A. Stoykova et al. (submitted). Mini-Oct2 is a 323 
amino acid protein containing the POU domain and 26 additional N-ter- 
minal and 44 C-terminal amino acids of Ott-2 and thus lacks most of 
the transactivation domain(s) (Gerster et al., 1990; Miiller-lmmergltick 
et al., 1990; Tanaka and Herr, 1990). The vectors pCMV-lOct4, 
pCMV-POct4, and pCMV-160ct4 expressing truncated Ott-4 protein 
were created by cutting different Ott-4 cDNA clones with EcoRl (in 5’ 
linker CCGGAATTCCGG) and Accl (in 3’ untranslated region at bp 
1018; Schdler et al., 199Oa) and by subsequent fill-in reaction and 
blunt-end ligation in pEVRF0 or pEVRF2, which had been restricted 
with Smal (Matthias et al., 1989). The Ott-4 sequences expressed 
in these vectors are numbered according to Schdler et al. (1990a): 
pCMVlOct4, bp 316 to 1018 (Accl) in pEVRF0; pCMV-16OcM; bp 
215 to 1018 in pEVRF2; pCMV-20ct4; bp 208 to 1018 in pEVRF0. 
pCMV-Gln-lOct4 and pCMV-Gln-POct4 were created by inserting the 
200 bp Hincll-Smal fragment containing the glutamine-rich sequence 
of hOct-2 (bp 348 to 547; numbering according to Clerc et al., 1988) 
into the unique BamHl site of the pEVRF vectors (Matthias et al., 1989) 
that had been blunt-ended with Klenow and dNTPs. 
ETA Expression Vectors 
pElA contains fragment 0 to 1771 bp of Ad5 cloned in the pBR322 
derivate pML-2. pH8APr-1-neo-12s and pHf3APr-I-neo-13s are de- 
scribed in Weigel et al. (1990); pH6APr-1-neo is described in Gunning 
et al. (1988). pH3G-13s and pH3G-13S/1098 were described in Lillie 
et al. (1986). 
Plasmids for In Vitro Transcription 
The 135 ElA RNA was produced with PBS-EIA (Ad5 13s ElA cloned 
in PBS), 12s EIA RNA with pGEM-12s (12s EIA cloned in pGEM-1). 
Ott-4 RNA was produced with the Juhachi clone as described pre- 
viously (Schdler et al., 199Oa). 
The 1 W oligonucleotide used in the EMSA has been described pre- 
viously (Scholer et al., 1989a). This probe contains the heavy chain 
gene enhancer octamer motif. 
Microextraction Procedure for the Preparation of Whole-Cell 
Extracts and the EMSA 
The microextraction procedure was performed as described previously 
(Schdler et al., 1990b). A standard binding reaction contained 6 ng of 
protein extract, 1 pg of poly(dl-dC), and 10,000 cpm of 1 W probe; any 
deviation from these values is outlined in the figure legends. To obtain 
protein-protein complexes, the standard binding reaction as de- 
scribed in Schiiler et al. (1989a) was modified: approximately 10 pg of 
a freshly prepared whole-cell extract (prepared either directly after cell 
harvest or from frozen pellet) was preincubated for 30 min at 2.5% in 
a volume of 10 nl containing 20 mM HEPES (pH 7.6) at 25°C 20% 
glycerol, 40 mM KCI, and 9 mM spermidine. Subsequently, 5 nl of 
radiolabeled 1 W probe (in 20% glycerol and 20 mM HEPES [pH 7.61 
at 25%) was added to the mixture and further incubated for 30 min at 
25°C. Neither poly(dl-dC) nor blue dye marker was used. In the anti- 
body experiment the Fab fragments were added with the IW probe. 
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